Edwards Lifesciences (EW) Depreciation & Amortization (CF) (2016 - 2026)
Edwards Lifesciences has reported Depreciation & Amortization (CF) over the past 17 years, most recently at $42.7 million for Q4 2025.
- For Q4 2025, Depreciation & Amortization (CF) changed 0.23% year-over-year to $42.7 million; the TTM value through Dec 2025 reached $156.6 million, up 0.9%, while the annual FY2025 figure was $156.6 million, 0.9% up from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 was $42.7 million at Edwards Lifesciences, up from $39.2 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $42.7 million in Q4 2025 and troughed at $32.4 million in Q1 2021.
- A 5-year average of $36.6 million and a median of $35.9 million in 2021 define the central range for Depreciation & Amortization (CF).
- Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 46.12% in 2021 and later fell 6.5% in 2024.
- Year by year, Depreciation & Amortization (CF) stood at $33.0 million in 2021, then increased by 7.27% to $35.4 million in 2022, then increased by 3.67% to $36.7 million in 2023, then increased by 16.08% to $42.6 million in 2024, then rose by 0.23% to $42.7 million in 2025.
- Business Quant data shows Depreciation & Amortization (CF) for EW at $42.7 million in Q4 2025, $39.2 million in Q3 2025, and $38.1 million in Q2 2025.